Page 114 - MBCA_FULL REPORT_FINAL_FOR_WEB

Study Drug(s) Target Biomarkers/ Combination Sponsor
Subtype
Temsirolimus, Metformin mTOR All MD Anderson Cancer Center
Everolimus, trametinib, mTOR, MEK, All National Cancer Institute
temozolomide and ABT- PARP, Wee1
888, or MK-1775
Temsirolimus, neratinib mTOR, HER2 HER2+ Puma Biotechnology
LGK974 Wnt pathway TripleNegative Novartis
(Porcupine)
JAK Ruxolitinib IL6/JAK/Stat All Dana-Farber/Harvard Cancer
pathway Center
Active, not recruiting Ruxolitinib JAK All Dana-Farber/Harvard Cancer
Center
Notch BMS-906024 Pan-Notch TripleNegative Bristol-Myers Squibb
BMS-906024 Pan-Notch TripleNegative Chemotherapy Bristol-Myers Squibb
PF-03084014 Notch All Docetaxel Pfizer
RAF/MEK/ERK
ALK Crizotinib/pazopanib/ ALK/VEG N/A MD Anderson Cancer Center
pemetrexed
X-396 ALK ALK+ Xcovery
Pazopanib VEGFR Hormone+ Letrozole or anastro- GlaxoSmithkline
zole
Active, not recruiting Cabozantinib (XL184 ) VEGFR2, c-Met TripleNegative Dana-Farber/Harvard Cancer
Center
ErbB Erlotinib/metformin ERB1 (EGFR) TripleNegative Astellas Pharma/Komen
Erlotinib ERB1 (EGFR) TripleNegative Chemotherapy and University of Washington
bevacizumab
Panitumumab ERB1 (EGFR) HER2- Nab-pacliatxel, car- Celgene/MD Anderson
boplatin, pluorouracil, Cancer Center
epirubicin, cyclophos-
phamide
Trastuzumab/lapatinib ErB1/ErB2 HER2+ GlaxoSmithKline
(HER2R)
Trastuzumab/lapatinib ErB2 (HER2R) HER2+ Combinations with University of Southern
capecitabine and California
cyclophosphamide
Trastuzumab, pertu- HER2 HER2+ Genentech, Susan G. Komen,
zumab GlaxoSmithKline
Trastuzumab, lapatinib HER2 HER2+ GlaxoSmithKline, Genentech
Lapatinib HER2 Hormone+_HER2- University of Kansas
Completed as of 8/1 High-dose lapatinib ErB2 (HER2R) HER2+ University of California, San
Francisco
AdHER2/neu dendritic ERB2 HER2+ National Cancer Institute
cell vaccine
ONT-380, T-DM1 ERB2 HER2+ Oncothyreon
ONT-380 ERB2 HER2+ Capecitabine and/or Oncothyreon
trastuzumab
Pertuzumab ErB2 HER2+ Protein-bound pacli- City of Hope
taxel/trastuzumab
Pertuzumab, trastuzum- ErB2 HER2+ Memorial Sloan Kettering
ab, paclitaxel
Pertuzumab/trastu- ErB2 HER2+ Genentech
zumab
Pertuzumab, trastuzum- ErB2 HER2+ Dana-Farber/Harvard
ab, and eribulin Cancer Center
PF-05280014 ErB2 HER2+ Paclitaxel Pfizer
MGAH22 ErB2 HER2+ Macrogenics